ASX Announcement

Spinal Cage FDA Submission Update

SYDNEY 16 AUGUST 2023– Allegra Orthopaedics Limited (**Allegra**) (ASX: AMT) is pleased to announce an update regarding the submission of the Sr–HT–Gahnite Spinal Cage Device (**Spinal Cage**) to the United States Food and Drug Administration (**FDA**).

The FDA are reviewing the device under the 510(k) pathway and have requested additional information. We will submit this information and anticipate a response can be provided within 2-3 months. Allegra will continue to update the market on any further developments of the Spinal Cage FDA submission.

Allegra Orthopaedics is the sole proprietor of the Sr-HT-Gahnite material and following FDA clearance, the Company will aim to apply the technology to fulfilling unmet needs across a broad range of applications, including Spine, Hip & Knee, and extremities.

This announcement has been authorised for release by the CEO of Allegra.

Contact details:

Robyn Slaughter
Company Secretary
T: +61 2 8072 1435

ABOUT ALLEGRA ORTHOPAEDICS:

We aim to help bring the freedom and happiness of pain-free movement to people's lives. We achieve this through providing the best possible solutions for patients, from world-wide industry leading orthopaedic products through to Australian innovations. Allegra's principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line. Allegra is also the exclusive distributor of Waldemar Link GmbH & Co. KG products in Australia. Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions. The Link products add to Allegra's well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb. The company is pleased to continue to build upon its extensive portfolio of patents. It has strong research relationships with universities, companies and surgeon inventors.